These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

209 related articles for article (PubMed ID: 17083268)

  • 41. Olmesartan medoxomil: the seventh angiotensin receptor antagonist.
    Gardner SF; Franks AM
    Ann Pharmacother; 2003 Jan; 37(1):99-105. PubMed ID: 12503943
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Can the pharmacokinetic characteristics of olmesartan medoxomil contribute to the improvement of blood pressure control?
    Wehling M
    Clin Ther; 2004; 26 Suppl A():A21-7. PubMed ID: 15291376
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Comparison of the efficacy of morning versus evening administration of olmesartan in uncomplicated essential hypertension.
    Smolensky MH; Hermida RC; Portaluppi F
    Chronobiol Int; 2007; 24(1):171-81. PubMed ID: 17364587
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Strong suppression of the renin-angiotensin system has a renal-protective effect in hypertensive patients: high-dose ARB with ACE inhibitor (Hawaii) study.
    Ohishi M; Takeya Y; Tatara Y; Yamamoto K; Onishi M; Maekawa Y; Kamide K; Rakugi H
    Hypertens Res; 2010 Nov; 33(11):1150-4. PubMed ID: 20703230
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Effects of renin-angiotensin system inhibition on end-organ protection: can we do better?
    Weir MR
    Clin Ther; 2007 Sep; 29(9):1803-24. PubMed ID: 18035185
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Chronic angiotensin II receptor blockade reduces (intra)renal vascular resistance in patients with type 2 diabetes.
    Fliser D; Wagner KK; Loos A; Tsikas D; Haller H
    J Am Soc Nephrol; 2005 Apr; 16(4):1135-40. PubMed ID: 15716329
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Efficacy of amlodipine and olmesartan medoxomil in patients with hypertension: the AZOR Trial Evaluating Blood Pressure Reductions and Control (AZTEC) study.
    Punzi H; Neutel JM; Kereiakes DJ; Shojaee A; Waverczak WF; Dubiel R; Maa JF
    Ther Adv Cardiovasc Dis; 2010 Aug; 4(4):209-21. PubMed ID: 20519261
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Effects of combination therapy with olmesartan and azelnidipine on serum osteoprotegerin in patients with hypertension.
    Uzui H; Morishita T; Nakano A; Amaya N; Fukuoka Y; Ishida K; Arakawa K; Lee JD; Tada H
    J Cardiovasc Pharmacol Ther; 2014 May; 19(3):304-9. PubMed ID: 24288395
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Renin-angiotensin-aldosterone system blockade is safe and effective in elderly hypertensive patients with and without impaired renal function.
    Ferri C; Ferri L
    High Blood Press Cardiovasc Prev; 2012 Dec; 19(4):197-8. PubMed ID: 23430662
    [No Abstract]   [Full Text] [Related]  

  • 50. Angiotensin receptor blocker added to previous antihypertensive agents on arteries of diabetic hypertensive patients.
    Savoia C; Touyz RM; Endemann DH; Pu Q; Ko EA; De Ciuceis C; Schiffrin EL
    Hypertension; 2006 Aug; 48(2):271-7. PubMed ID: 16785331
    [TBL] [Abstract][Full Text] [Related]  

  • 51. [Pharmacological profiles and clinical effects of olmesartan medoxomil, a novel angiotensin II receptor blocker].
    Sada T; Mizuno M
    Nihon Yakurigaku Zasshi; 2004 Oct; 124(4):257-69. PubMed ID: 15467259
    [TBL] [Abstract][Full Text] [Related]  

  • 52. A double-blind, dose-response study of the efficacy and safety of olmesartan medoxomil in children and adolescents with hypertension.
    Hazan L; Hernández Rodriguez OA; Bhorat AE; Miyazaki K; Tao B; Heyrman R;
    Hypertension; 2010 Jun; 55(6):1323-30. PubMed ID: 20385971
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Efficacy and safety of olmesartan medoxomil and hydrochlorothiazide compared with benazepril and amlodipine besylate.
    Kereiakes DJ; Neutel JM; Punzi HA; Xu J; Lipka LJ; Dubiel R
    Am J Cardiovasc Drugs; 2007; 7(5):361-72. PubMed ID: 17953475
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Strategies to meet lower blood pressure goals with a new standard in angiotensin II receptor blockade.
    Smith DH
    Am J Hypertens; 2002 Oct; 15(10 Pt 2):108S-114S. PubMed ID: 12383591
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Subgroup analyses of an efficacy and safety study of concomitant administration of amlodipine besylate and olmesartan medoxomil: evaluation by baseline hypertension stage and prior antihypertensive medication use.
    Oparil S; Lee J; Karki S; Melino M
    J Cardiovasc Pharmacol; 2009 Nov; 54(5):427-36. PubMed ID: 19730391
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Antihypertensive, insulin-sensitising and renoprotective effects of a novel, potent and long-acting angiotensin II type 1 receptor blocker, azilsartan medoxomil, in rat and dog models.
    Kusumoto K; Igata H; Ojima M; Tsuboi A; Imanishi M; Yamaguchi F; Sakamoto H; Kuroita T; Kawaguchi N; Nishigaki N; Nagaya H
    Eur J Pharmacol; 2011 Nov; 669(1-3):84-93. PubMed ID: 21816148
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Blood pressure-lowering efficacy of olmesartan relative to other angiotensin II receptor antagonists: an overview of randomized controlled studies.
    Zannad F; Fay R
    Fundam Clin Pharmacol; 2007 Apr; 21(2):181-90. PubMed ID: 17391291
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Efficacy of Sevikar® compared to the combination of perindopril plus amlodipine on central arterial blood pressure in patients with moderate-to-severe hypertension: Rationale and design of the SEVITENSION study.
    Ruilope LM; Schaefer A
    Contemp Clin Trials; 2011 Sep; 32(5):710-6. PubMed ID: 21586342
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Effect of olmesartan medoxomil on atherosclerosis: clinical implications of the emerging evidence.
    Takai S; Miyazaki M
    Am J Cardiovasc Drugs; 2006; 6(6):363-6. PubMed ID: 17192125
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Benefits of the angiotensin II receptor antagonist olmesartan in controlling hypertension and cerebral hemodynamics after stroke.
    Matsumoto S; Shimodozono M; Miyata R; Kawahira K
    Hypertens Res; 2009 Nov; 32(11):1015-21. PubMed ID: 19745828
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 11.